137 related articles for article (PubMed ID: 36229048)
1. A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR).
Patel J; Bass D; Beishuizen A; Bocca Ruiz X; Boughanmi H; Cahn A; Colombo H; Criner GJ; Davy K; de-Miguel-Díez J; Doreski PA; Fernandes S; François B; Gupta A; Hanrott K; Hatlen T; Inman D; Isaacs JD; Jarvis E; Kostina N; Kropotina T; Lacherade JC; Lakshminarayanan D; Martinez-Ayala P; McEvoy C; Meziani F; Monchi M; Mukherjee S; Muñoz-Bermúdez R; Neisen J; O'Shea C; Plantefeve G; Schifano L; Schwab LE; Shahid Z; Shirano M; Smith JE; Sprinz E; Summers C; Terzi N; Tidswell MA; Trefilova Y; Williamson R; Wyncoll D; Layton M
Eur Respir J; 2023 Feb; 61(2):. PubMed ID: 36229048
[TBL] [Abstract][Full Text] [Related]
2. MRI of the joint and evaluation of the granulocyte-macrophage colony-stimulating factor-CCL17 axis in patients with rheumatoid arthritis receiving otilimab: a phase 2a randomised mechanistic study.
Genovese MC; Berkowitz M; Conaghan PG; Peterfy C; Davy K; Fisheleva E; Gupta A; Inman D; Janiczek R; Layton M; Mitchell N; Patel J; Roberts A; Saurigny D; Smith JE; Williamson R; Tak PP
Lancet Rheumatol; 2020 Nov; 2(11):e666-e676. PubMed ID: 38279363
[TBL] [Abstract][Full Text] [Related]
3. Anti-granulocyte-macrophage colony-stimulating factor antibody otilimab in patients with hand osteoarthritis: a phase 2a randomised trial.
Schett G; Bainbridge C; Berkowitz M; Davy K; Fernandes S; Griep E; Harrison S; Gupta A; Lloyd-Hughes J; Roberts A; Layton M; Nowak NA; Patel J; Rech J; Smith JE; Watts S; Tak PP
Lancet Rheumatol; 2020 Oct; 2(10):e623-e632. PubMed ID: 38273625
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, patient-reported outcomes, and safety of the anti-granulocyte macrophage colony-stimulating factor antibody otilimab (GSK3196165) in patients with rheumatoid arthritis: a randomised, phase 2b, dose-ranging study.
Buckley CD; Simón-Campos JA; Zhdan V; Becker B; Davy K; Fisheleva E; Gupta A; Hawkes C; Inman D; Layton M; Mitchell N; Patel J; Saurigny D; Williamson R; Tak PP
Lancet Rheumatol; 2020 Nov; 2(11):e677-e688. PubMed ID: 38279364
[TBL] [Abstract][Full Text] [Related]
5. Anti-Granulocyte-Macrophage Colony-Stimulating Factor Monoclonal Antibody Gimsilumab for COVID-19 Pneumonia: A Randomized, Double-Blind, Placebo-controlled Trial.
Criner GJ; Lang FM; Gottlieb RL; Mathews KS; Wang TS; Rice TW; Madduri D; Bellam S; Jeanfreau R; Case AH; Glassberg MK; Lyon GM; Ahmad K; Mendelson R; DiMaio JM; Tran MP; Spak CW; Abbasi JA; Davis SG; Ghamande S; Shen S; Sherman L; Lowry S
Am J Respir Crit Care Med; 2022 Jun; 205(11):1290-1299. PubMed ID: 35290169
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
[TBL] [Abstract][Full Text] [Related]
7. Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial.
Temesgen Z; Burger CD; Baker J; Polk C; Libertin CR; Kelley CF; Marconi VC; Orenstein R; Catterson VM; Aronstein WS; Durrant C; Chappell D; Ahmed O; Chappell G; Badley AD;
Lancet Respir Med; 2022 Mar; 10(3):237-246. PubMed ID: 34863332
[TBL] [Abstract][Full Text] [Related]
8. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp KA; Gooderham M; Jenkins R; Vender R; Szepietowski JC; Wagner T; Hunt B; Souberbielle B;
Br J Dermatol; 2019 Jun; 180(6):1352-1360. PubMed ID: 30207587
[TBL] [Abstract][Full Text] [Related]
9. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
10. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
Cremer PC; Abbate A; Hudock K; McWilliams C; Mehta J; Chang SY; Sheng CC; Van Tassell B; Bonaventura A; Vecchié A; Carey B; Wang Q; Wolski KE; Rajendram P; Duggal A; Wang TS; Paolini JF; Trapnell BC;
Lancet Rheumatol; 2021 Jun; 3(6):e410-e418. PubMed ID: 33754144
[TBL] [Abstract][Full Text] [Related]
11. Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial.
Bosteels C; Maes B; Van Damme K; De Leeuw E; Declercq J; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
Trials; 2020 Jun; 21(1):491. PubMed ID: 32503663
[TBL] [Abstract][Full Text] [Related]
12. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.
Temesgen Z; Kelley CF; Cerasoli F; Kilcoyne A; Chappell D; Durrant C; Ahmed O; Chappell G; Catterson V; Polk C; Badley A; Marconi VC;
Thorax; 2023 Jun; 78(6):606-616. PubMed ID: 35793833
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
16. MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F; Tak PP; Østergaard M; Stoilov R; Wiland P; Huizinga TW; Berenfus VY; Vladeva S; Rech J; Rubbert-Roth A; Korkosz M; Rekalov D; Zupanets IA; Ejbjerg BJ; Geiseler J; Fresenius J; Korolkiewicz RP; Schottelius AJ; Burkhardt H
Ann Rheum Dis; 2015 Jun; 74(6):1058-64. PubMed ID: 24534756
[TBL] [Abstract][Full Text] [Related]
17. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
Temesgen Z; Assi M; Shweta FNU; Vergidis P; Rizza SA; Bauer PR; Pickering BW; Razonable RR; Libertin CR; Burger CD; Orenstein R; Vargas HE; Palraj R; Dababneh AS; Chappell G; Chappell D; Ahmed O; Sakemura R; Durrant C; Kenderian SS; Badley AD
Mayo Clin Proc; 2020 Nov; 95(11):2382-2394. PubMed ID: 33153629
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
François B; Jafri HS; Chastre J; Sánchez-García M; Eggimann P; Dequin PF; Huberlant V; Viña Soria L; Boulain T; Bretonnière C; Pugin J; Trenado J; Hernandez Padilla AC; Ali O; Shoemaker K; Ren P; Coenjaerts FE; Ruzin A; Barraud O; Timbermont L; Lammens C; Pierre V; Wu Y; Vignaud J; Colbert S; Bellamy T; Esser MT; Dubovsky F; Bonten MJ; Goossens H; Laterre PF;
Lancet Infect Dis; 2021 Sep; 21(9):1313-1323. PubMed ID: 33894131
[TBL] [Abstract][Full Text] [Related]
19. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma.
Advani R; Chao NJ; Horning SJ; Blume KG; Ahn DK; Lamborn KR; Fleming NC; Bonnem EM; Greenberg PL
Ann Intern Med; 1992 Feb; 116(3):183-9. PubMed ID: 1345803
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Rilinger J; Kern WV; Duerschmied D; Supady A; Bode C; Staudacher DL; Wengenmayer T
Trials; 2020 Jun; 21(1):470. PubMed ID: 32493514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
